Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001049279 | SCV001213324 | uncertain significance | Intellectual disability, autosomal dominant 1 | 2019-02-18 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine with serine at codon 1233 of the MBD5 protein (p.Asn1233Ser). The asparagine residue is highly conserved and there is a small physicochemical difference between asparagine and serine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with MBD5-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Centre for Mendelian Genomics, |
RCV001049279 | SCV001366964 | uncertain significance | Intellectual disability, autosomal dominant 1 | 2019-10-03 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PM2. |
Ambry Genetics | RCV004629422 | SCV005130314 | uncertain significance | Inborn genetic diseases | 2024-05-12 | criteria provided, single submitter | clinical testing | The c.3698A>G (p.N1233S) alteration is located in exon 12 (coding exon 7) of the MBD5 gene. This alteration results from a A to G substitution at nucleotide position 3698, causing the asparagine (N) at amino acid position 1233 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |